Loki zupa (Luooukezupa) decoction reduced airway inflammation in an OVA-induced asthma mouse model

Wei, Ying; Abduwaki, Muhammadjan; Li, Mihui; Luo, Qingli; Sun, Jing; Lv, Yubao; Nurahmat, Mammat; Dong, Jingcheng

doi:10.1186/s13020-016-0094-9

Cited by 22 publications

(16 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood serum and bronchoalveolar lavage fluid samples were collected according to the method described in reference (Wei et al, 2016 ). In brief, blood samples preserved for 2 h at 4°C before centrifugation.…”

Section: Methodsmentioning

confidence: 99%

Establishment and Evaluation of a Rat Model of Sidestream Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease

et al. 2018

Self Cite

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a common cause of mortality worldwide. The current lack of an animal model that can be established within a certain time frame and imitate the unique features of the disease is a major limiting factor in its study. The present study established and evaluated an animal model of COPD that represents the early and advanced stage features using short-, middle-, and long-term sidestream cigarette smoke (CS) exposure. One hundred and nine Sprague–Dawley rats were randomly divided into 10 groups for different periods of sidestream CS exposure or no exposure (i.e., normal groups). The rats were exposed to CS from 3R4F cigarettes in an exposure chamber. Histological analysis was performed to determine pathological changes. We also conducted open-field tests, lung function evaluations, and cytokine analysis of the blood serum, bronchoalveolar lavage fluid, and lung tissue. The lung tissue protein levels, blood gases, and were also analyzed. As the CS exposure time increased, the indicators associated with oxidative stress, inflammatory responses, and airway remodeling were greater in the CS exposure groups than in the normal group. At 24 and 36 weeks, the COPD model rats displayed the middle- and advanced-stage features of COPD, respectively. In the 8-week CS exposure group, after the CS exposure was stopped for 4 weeks, inflammatory responses and oxidative responses were ameliorated and lung function exacerbation was reduced compared with the 12-week CS exposure group. Therefore, we established a more adequate rat model of sidestream CS induced COPD, which will have great significance for a better understanding of the pathogenesis of COPD and drug effectiveness evaluation.

show abstract

Section: Methodsmentioning

confidence: 99%

Establishment and Evaluation of a Rat Model of Sidestream Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Elevated Th2 cells are characteristic features of allergic asthma ( Umetsu and DeKruyff, 1997 ). Th2 cytokines, in particular, IL-4, IL-5, and IL-13 play a key role in initiating and sustaining the asthmatic response by regulating the production of IgE and the growth, differentiation, and recruitment of mast cells, basophils, and eosinophils ( Hams and Fallon, 2012 ; Lloyd and Saglani, 2013 ; Sun et al ., 2016 ). In this study, we examined mRNA expression changes of IL-4, IL-5, and IL-13 in lung tissue and BALF cells, which were elevated by 537%, 419%, and 382%, respectively in the lung tissue of OVA-induced asthma group compared to PBS control group ( Fig.…”

Section: Resultsmentioning

confidence: 99%

Suppressive Effect of 4-Hydroxy-2-(4-Hydroxyphenethyl) Isoindoline-1,3-Dione on Ovalbumin-Induced Allergic Asthma

Huang

Lee

Kim

et al. 2018

Biomolecules & Therapeutics

View full text Add to dashboard Cite

4-Hydroxy-2-(4-hydroxyphenethyl)isoindoline-1,3-dione (PD1) is a synthetic phthalimide derivative of a marine compound. PD1 has peroxisome proliferator-activated receptor (PPAR) γ agonistic and anti-inflammatory effects. This study aimed to investigate the effect of PD1 on allergic asthma using rat basophilic leukemia (RBL)-2H3 mast cells and an ovalbumin (OVA)-induced asthma mouse model. In vitro, PD1 suppressed β-hexosaminidase activity in RBL-2H3 cells. In the OVA-induced allergic asthma mouse model, increased inflammatory cells and elevated Th2 and Th1 cytokine levels were observed in bronchoalveolar lavage fluid (BALF) and lung tissue. PD1 administration decreased the numbers of inflammatory cells, especially eosinophils, and reduced the mRNA and protein levels of the Th2 cytokines including interleukin (IL)-4 and IL-13, in BALF and lung tissue. The severity of inflammation and mucin secretion in the lungs of PD1-treated mice was also less. These findings indicate that PD1 could be a potential compound for anti-allergic therapy.

show abstract

“…The Th2 cytokines IL-4, IL-5, and IL-13 are believed to be associated with eosinophilic inflammation ( Hinks et al, 2015 ). Animal study had shown an anti-inflammatory effect in reducing Th2 cytokines of Loki zupa in OVA-induced asthma model challenged with OVA for 1 week ( Wei et al, 2016 ). The discrepancy between the results of this study and the animal experiment data may indicate that Loki zupa may be effective in alleviating Th2 type inflammation with a short asthma history.…”

Section: Discussionmentioning

confidence: 99%

“…Previous investigations demonstrated that Loki zupa was the best and strongest formula to treatment respiratory diseases in Uyghur traditional medicine. Animal research results showed that Loki zupa decoction reduced airway hyperresponsiveness, attenuated airway inflammation, promoted Th1, and suppressed Th2 cell functions in an OVA-induced asthma mouse model ( Wei et al, 2016 ). However, the clinical evidences of the efficacy of Loki zupa in asthma patients are rare.…”

Section: Introductionmentioning

confidence: 99%

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Loki zupa in Patients With Chronic Asthma

Wei

Abduwaki³

et al. 2018

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

The purpose of this study was to evaluate the efficacy and safety of Uyghur medical formula Loki zupa in patients with chronic asthma. Adult patients with chronic asthma randomly received placebo or Loki zupa as add-on to inhaled corticosteroids (ICS) maintenance treatment. Loki zupa or mimics was administered orally 10 ml per time, three times a day for 8 weeks. The primary endpoints were asthma control test (ACT) score and peak expiratory flow (PEF). The secondary endpoints were acute exacerbation rate, lung function, night waking days, and symptom-free days in the near 2 weeks, Asthma Quality of Life Questionnaire (AQLQ) score and some inflammatory cytokines in peripheral blood. A total of 240 adult patients with chronic asthma were enrolled, and 218 patients were randomized to placebo (n = 109) or Loki zupa (n = 109) in addition to ICS for 8 weeks. Treatment with Loki zupa resulted in significant improvement in ACT score compared to the placebo group (p = 0.002). Furthermore, oral taken of Loki zupa increased the PEF obviously (p = 0.026). Loki zupa treatment did not improve the forced expiratory volume in 1 s (FEV1, p = 0.131) and FEV1/FVC compared to the placebo treatment (p = 0.805). The placebo group had higher rates of acute exacerbations than the Loki zupa group (6.3% vs. 0, p = 0.027). Subjects randomized to Loki zupa had increased daytime symptom-free days within 2 weeks than placebo (p = 0.016). However, Loki zupa had no effect on night waking days in the near 2 weeks (p = 0.369) and AQLQ score (p = 0.113). No significant effect was found on inflammatory cytokines (IL-2, IL-4, IL-5, IL-10, IL-13, IL-17, IL-33, IFN-γ, and TGF-β) between the two groups (p > 0.05). No adverse events and severe asthma exacerbations were recorded in the two groups (p > 0.05). Loki zupa add-on to standard ICS produced clinically significant improvements in ACT score, PEF, daytime symptom-free days and acute exacerbation in patients with chronic asthma.Clinical trial: This study is registered at http://www.chictr.org.cn/ with identifier number ChiCTR-IPR-16008106.

show abstract

Loki zupa (Luooukezupa) decoction reduced airway inflammation in an OVA-induced asthma mouse model

Cited by 22 publications

References 37 publications

Establishment and Evaluation of a Rat Model of Sidestream Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease

Establishment and Evaluation of a Rat Model of Sidestream Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease

Suppressive Effect of 4-Hydroxy-2-(4-Hydroxyphenethyl) Isoindoline-1,3-Dione on Ovalbumin-Induced Allergic Asthma

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Loki zupa in Patients With Chronic Asthma

Contact Info

Product

Resources

About